Physician profile
Robert Butterwick
NPI 1174630024
$6,923.99
in general payments reported to CMS, 2019-2025
26 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $593 · 2021: $865 · 2022: $1,046 · 2023: $1,149 · 2024: $1,329 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,569 · Entertainment: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.96 |
| Entertainment | $174.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,169.15 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $900.49 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $775.75 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $766.64 | 2020-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $627.17 | 2019-2025 | Precision 1, Precision7 |
| Sun Pharmaceutical Industries INC. | $396.53 | 2022-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $251.54 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $226.93 | 2024 | Xdemvy |
| Allergan, INC. | $194.71 | 2022 | |
| Harrow Eye, LLC | $192.68 | 2025 | Vevye |
| Optos, INC. | $174.17 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abb Con-Cise Optical Group LLC | $172.69 | 2025 | Contact Lens, Spectacle Lenses |
| Oyster Point Pharma, INC. | $172.61 | 2022-2023 | Tyrvaya |
| Sight Sciences, INC. | $136.68 | 2022 | |
| Abbvie INC. | $119.66 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $117.38 | 2025 | Tecnis Iol |
| Lkc Technologies, INC. | $113.45 | 2023-2025 | |
| Dompe US, INC. | $111.25 | 2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $97.55 | 2024 | Syfovre |
| Ivantis, INC | $88.23 | 2020 | |
| Carl Zeiss Meditec, INC. | $40.00 | 2019 | |
| Menicon America INC | $22.14 | 2019 | |
| Shire North American Group INC | $16.56 | 2019 | |
| Kala Pharmaceuticals, INC. | $14.27 | 2021 | |
| Maculogix, INC. | $14.23 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Butterwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.